Date: Jun 28, 2018 10:00 AM PDT Registration: https://zoom.us/webinar/register/WN_HwHKpWGjQeigeE_6tqjUcw There is evidence that the efficiency, accuracy and reproducibility of pathologic diagnosis can be enhanced by digital technologies and...

When: Wed, Jun 6, 2018 10:00 AM - 11:00 AM PDT Register Now   PD-L1 is seen as the current breakthrough therapeutic target in immuno-oncology. Following recent clinical advances, PD-L1 expression has become a key factor in determining...

25 years ago when I started my clinical rotations as a third-year medical student, my interest in pathology across the medical and surgical specialties was usually met with a question such as "Why do you want to do pathology? You are going to...

During the event, we will be showcasing our entire digital pathology portfolio. Here we are particularly proud to share our work in advancing PD-L1 testing based on the patented VirtualTripleStaining™ and its utility in automated assessment...

HalioDx receives CLIA Compliance for its laboratory based in Marseille Immunoscore® Colon, is now available to US patients in selected states with a turnaround time of 10 days Marseille, June 21, 2017 - HalioDx announced today that...

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...